TCR² Therapeutics Inc., based in Cambridge, is a clinical-stage company that develops T-cell therapies for patients with cancer. In a statement, TCR² said it signed a long-term, full-building lease for an existing 85,000 sq. ft. facility. The company will build-out the space to be used for quality control laboratories and offices as well as clinical and commercial production of gavo-cel, the company’s lead product targeting solid tumors. According to a federal form, 15 years is the initial term for the lease at 9950 Medical Center Drive.
{iframe}https://www.mymcmedia.org/massachusetts-based-cell-therapy-company-coming-to-rockville/{/iframe}